Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

163 results
Display

The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study

Shim M, Bang WJ, Oh CY, Lee YS, Jeon SS, Ahn H, Ju YS, Cho JS

BACKGROUND: The objective of this study was to investigate whether androgen deprivation therapy (ADT) with gonadotropin-releasing hormone agonist (GnRHa) in prostate cancer (Pca) patients is associated with cardiovascular disease in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide

Shim M, Bang WJ, Oh CY, Lee YS, Cho JS

PURPOSE: To investigate the changes in testosterone levels and rates of chemical castration following androgen-deprivation therapy (ADT) with goserelin, triptorelin, and leuprolide. MATERIALS AND METHODS: We retrospectively reviewed the medical records...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer

Zhang Z, Huang H, Feng F, Wang J, Cheng N

OBJECTIVE: This study aims to evaluate the effects and pregnancy outcomes of gonadotropin-releasing hormone agonist (GnRH agonist) combined with aromatase inhibitor (AI) in preserving the fertility of obese women with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropin-releasing hormone agonist alone and those treated with combined growth hormone therapy

Kim MS, Koh HJ, Lee GY, Kang DH, Kim SY

PURPOSE: This study aimed to investigate the outcomes of gonadotropin-releasing hormone agonist (GnRHa) therapy with or without growth hormone (GH) therapy for girls with idiopathic central precocious puberty (CPP). METHODS: The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Posterior reversible encephalopathy syndrome in a woman who used gonadotropin-releasing hormone agonists: a case report

Lee M, Kim TH, Kim SJ, Jee BC

Posterior reversible encephalopathy syndrome (PRES) is a newly described adverse effect possibly associated with gonadotropin-releasing hormone (GnRH) agonist therapy. We report a case of PRES after 2 doses of depot...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial

Shin JJ, Park KE, Choi YM, Kim HO, Choi DH, Lee WS, Cho JH

OBJECTIVE: To prospectively evaluate the efficacy and safety of a fixed early gonadotropin-releasing hormone (GnRH) antagonist protocol compared to a conventional midfollicular GnRH antagonist protocol and a long GnRH agonist...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the clinical outcome of frozen-thawed embryo transfer with and without pretreatment with a gonadotropin-releasing hormone agonist

Kang J, Park J, Chung D, Lee SH, Park EY, Han KH, Choi SJ, Chung IB, Han HD, Jung YS

OBJECTIVE: To describe the clinical outcomes of frozen-thawed embryo transfer (FET) with artificial preparation of the endometrium, using a combination of estrogen (E2) and progesterone (P4) with or without a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study

Moradan S

OBJECTIVES: There are many drugs for of symptomatic fibroids. Gonadotropin-releasing hormone (GnRH) agonists are the well known drugs. Also, aromatase inhibitors are effective. All published studies surveyed the effect of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level

Park J, Hwang TH, Kim YD, Han HS

PURPOSE: Reported changes in body mass index (BMI) in central precocious puberty (CPP) during and after gonadotropin-releasing hormone analog (GnRHa) treatment are inconsistent. We, therefore, investigated auxological parameters in GnRHa-treated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer

Kim SH, Choi J, Park CS, Kim HA, Noh WC, Seong MK

PURPOSE: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The effect of overweight on the luteinizing hormone level after gonadorelin stimulation test in girls with idiopathic central precocious puberty

Lee HY, Lee YJ, Ahn MB, Cho WK, Suh BK

PURPOSE: We investigated the effect of overweight on luteinizing hormone (LH) levels after a gonadorelin stimulation test in Korean girls with idiopathic central precocious puberty (CPP). METHODS: Medical records of 234...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing in vitro fertilization

Lee H, Choi HJ, Yang KM, Kim MJ, Cha SH, Yi HJ

OBJECTIVES: We investigated whether luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist (E/G-ant) priming protocol improves clinical outcomes in poor responders to controlled ovarian stimulation for in vitro...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of immunocontraceptive vaccine composed of gonadotropin-releasing hormone conjugated with granulocyte-macrophage colony-stimulating factor in male rats

Park BJ, Kim YH, Ahn HS, Han SH, Go HJ, Lee JB, Park SY, Song CS, Lee SW, Choi IS

Surgical castration performed to reduce male-associated problems results in pain and microbial infections in male animals. Therefore, immunocontraception, which is mediated by the animal's own antibodies against reproductive hormones, has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series

Lee D, Kim SJ, Hong YH, Kim SK, Jee BC

OBJECTIVE: To report an efficacy of gonadotropin releasing hormone (GnRH) antagonist administration after freezing of all embryos for treatment of early type ovarian hyperstimulation syndrome (OHSS). METHODS: In 10 women who...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reversible Cerebral Vasoconstriction Syndrome Presenting with Bilateral Occipital Hemorrhage after the Subcutaneous Injection of Synthetic Gonadotropin Releasing Hormone

Chung I, Yoo D, Jung C, Han MK

Reversible cerebral vasoconstriction syndrome (RCVS) is a heterogeneous group of cerebrovascular disease. The pathophysiology of RCVS is unknown, but a disturbance in cerebral vascular tone is one of hypothesis. Long-term...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome

Chappell N, Gibbons WE

The purpose of this paper is to assimilate all data pertaining to the use of gonadotropin-releasing hormone (GnRH) antagonists in in vitro fertilization cycles after ovulation trigger to reduce the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty

Kim SW, Kim YB, Lee JE, Kim NR, Lee WK, Ku JK, Kim EJ, Jung SH, Chung WY

PURPOSE: This study aimed to investigate the influence of gonadotropin releasing hormone agonist (GnRHa) treatment on the weight and body mass index (BMI) of girls who were diagnosed with idiopathic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erratum to: Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density

Cho YH, Um MJ, Kim SJ, Kim SA, Jung H

The author and author's affiliation should be corrected.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty

Yang WJ, Ko KH, Lee KH, Hwang IT, Oh YJ

PURPOSE: The effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on body mass index (BMI) are controversial in girls with central precocious puberty (CPP). We therefore evaluated auxological parameters during GnRHa...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty

Park J, Kim JH

PURPOSE: Gonadotropin-releasing hormone agonist (GnRHa) is used as a therapeutic agent for central precocious puberty (CPP); however, increased obesity may subsequently occur. This study compared body mass index (BMI) and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr